The authors show depletion of Malat1 lncRNA expression in TNBC decreases the immunosuppressive properties of the tumor microenvironment while increasing T-cell infiltration. The data highlight the potential of targeting Malat1 in combination with immunostimulatory therapies to improve response.

The immune checkpoint VISTA is upregulated on endothelial cells in cancer and selectively prevents T-cell extravasation into tumors. The data highlight a mechanism behind T-cell exclusion and provide a deeper understanding of factors shaping the tumor immune microenvironment.

Understanding immune responses in advanced melanoma patients benefitting from ipilimumab and bevacizumab treatment holds promise for identifying potential functional targets. The authors identify EDIL3 in immunosuppressive CAFs as a putative immunogenic target linked to T-cell immune exclusion from the tumor microenvironment.

In this study, FOXO1 inhibition enables the generation of non-activated CAR T cells that exert a more efficient antitumoral response than CAR T cells generated with standard procedures, suggesting ways to enhance the efficacy of CAR T-cell therapy.

Sequential use of feeder cells expressing membrane-bound IL21 and then IL15 enables harnessing of the respective cytokine benefits and generates high yields of functional NK cells. The study highlights an optimized workflow to potentially improve their therapeutic utility.

How human slan⁺ monocytes mediate therapeutic antibody-dependent cellular cytotoxicity is incompletely understood. The authors show that slan⁺ monocytes mediate rituximab-, daratumumab- and magrolimab-dependent trogocytosis that leads to a form of lytic cancer cell death known as trogoptosis.

The transitional immune and genomic landscapes during OSCC tumorigenesis are elucidated in a mouse model; recapitulation of human disease is demonstrated. The data highlight use of the OSCC model to assess efficacy of immunotherapy.